Bertrand Lehuu

Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France.

BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy.

Flamel Technologies SA engages in the research, development and commercialization of pharmaceutical products. Its portfolio includes Bloxiverz, Vazculep, Micropump, LiquiTime, Trigger Lock and Medusa. The company was founded by Gérard Soula in August 1990 and is headquartered in Vénissieux, France.

Aquapharm Biodiscovery Ltd. discovers and develops drugs. It develops products for application across the pharmaceutical, personal care and nutrition sectors. The company offers antibiotics, inflammation & dermatology, oxidative stress, high value ingredients and anti-oxidant ingredients. Aquapharm Biodiscovery was founded by Kathryn Fraser and Andrew Mearns Spragg on April 11, 2000 and is headquartered in Edinburgh, GB.

The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris.

PharmaSwiss SA engages in the provision of healthcare solutions. It also offers consulting services. The company was founded on January 24, 2000 and is headquartered in Zug, Switzerland.